



Correction: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity

Sarah Al-dulaimi · Ross Thomas · Sheila Matta ·
Terry Roberts

Published online: 15 November 2025
© The Author(s) 2025

Correction to: Biogerontology
<https://doi.org/10.1007/s10522-025-10315-x>


In this article, the wrong figures appeared in Figs. 1, 2 and 3. The incorrect and correct versions of Figs. 1, 2 and 3 are provided below:

The original article can be found online at <https://doi.org/10.1007/s10522-025-10315-x>.

S. Al-dulaimi · R. Thomas · T. Roberts (✉)
Centre for Genome Engineering and Maintenance,
Division of Biosciences, Department of Life Sciences,
College of Health and Life Sciences, Brunel University
London, Uxbridge UB8 3PH, UK
e-mail: terry.roberts@brunel.ac.uk

S. Matta
Respiratory Clinical Research Facility, Royal Brompton
Hospital, Fulham Road, London SW3 6HP, UK

Incorrect version of Fig. 1:



Telomere length of breast cancer cells and normal cells treated with epitalon. **A** 21NT cells **B** BT474 cells. Both cells were treated for 4 days with varying concentrations of epitalon. (0.1, 0.2, 0.5 and 1 µg/ml). Untreated cells were used as a control.

C Telomere length of IBR.3 cells (P.14) treated with 1 µg / ml epitalon for 3 weeks. **D** telomere length of HMEC (P.14) treated with 1 µg /ml epitalon for 3 weeks. Untreated cells were included as a control

Correct Version of Fig. 1:





Fig. 1 Telomere length of breast cancer cells and normal cells treated with epitalon. **A** 21NT cells **B** BT474 cells. Both cells were treated for 4 days with varying concentrations of epitalon. (0.1, 0.2, 0.5 and 1 ug/ml). Untreated cells were used as a con-

trol. **C** Telomere length of IBR.3 cells (P.14) treated with 1 μ g/ml epitalon for 3 weeks. **D** telomere length of HMEC (P.14) treated with 1 μ g/ml epitalon for 3 weeks. Untreated cells were included as a control

Incorrect Version of Fig. 2:



hTERT expression (RQ) and telomerase enzyme activity in breast cancer cells and normal fibroblast cells treated with epitalon. **A** and **B** hTERT expression and telomerase activity for 21NT treated with 0.5 and 1 µg/ml of epitalon for 4 days. **C** and **D** hTERT expression and telomerase activity of BT474 treated with 0.5 and 1 µg/ml of epitalon for 4 days. PC3 was

included as a positive control for telomerase activity. **E** and **F** hTERT expression and telomerase activity for IBR.3 were treated with 1 µg/ml of epitalon for three weeks. **G** and **H** hTERT expression and telomerase activity for HMEC treated with 1 µg/ml of epitalon for three weeks

Correct Version of Fig. 2:





Fig. 2 hTERT expression (RQ) and telomerase enzyme activity in breast cancer cells and normal fibroblast cells treated with epitalon. **A** and **B** hTERT expression and telomerase activity for 21NT treated with 0.5 and 1 µg/ml of epitalon for 4 days. **C** and **D** hTERT expression and telomerase activity of BT474 treated with 0.5 and 1 µg/ml of epitalon for 4 days.

PC3 was included as a positive control for telomerase activity. **E** and **F** hTERT expression and telomerase activity for IBR.3 were treated with 1 µg/ml of epitalon for three weeks. **G** and **H** hTERT expression and telomerase activity for HMEC treated with 1 µg/ml of epitalon for three weeks

Incorrect Version of Fig. 3:



ALT activity in breast cancer cells and normal cells treated with epitalon. **A** and **B** ALT activity in 21NT and BT474 treated with 1 µg/ml of epitalon for 4 days. Untreated cells and the ALT positive U2OS were included as controls. **C** IBR.3 and **D** HMEC treated with 1 µg/ml of epitalon for three weeks. **E** Immunofluorescence to detect PML bodies in 21NT and

BT474 cells treated with epitalon for 4 days. The colocalization PML bodies (green staining) within the nucleus (blue staining) for 21NT and BT474 treated with epitalon indicated the presence of ALT. PML bodies were detected using Leica microscope with X 100 objective

Correct Version of Fig. 3:




Fig. 3 ALT activity in breast cancer cells and normal cells treated with epitalon. **A** and **B** ALT activity in 21NT and BT474 treated with 1 µg/ml of epitalon for 4 days. Untreated cells and the ALT positive U2OS were included as controls. **C** IBR.3 and **D** HMEC treated with 1 µg/ml of epitalon for three weeks. **E** Immunofluorescence to detect PML bodies in 21NT

and BT474 cells treated with epitalon for 4 days. The colocalization PML bodies (green staining) within the nucleus (blue staining) for 21NT and BT474 treated with epitalon indicated the presence of ALT. PML bodies were detected using Lecia microscope with X 100 objective

The original article has been corrected.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the

material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.